A detailed history of Acuta Capital Partners, LLC transactions in Insmed Inc stock. As of the latest transaction made, Acuta Capital Partners, LLC holds 107,500 shares of INSM stock, worth $7.53 Million. This represents 7.94% of its overall portfolio holdings.

Number of Shares
107,500
Previous 72,100 49.1%
Holding current value
$7.53 Million
Previous $4.83 Million 62.46%
% of portfolio
7.94%
Previous 5.2%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$62.0 - $79.01 $2.19 Million - $2.8 Million
35,400 Added 49.1%
107,500 $7.85 Million
Q2 2024

Aug 14, 2024

BUY
$22.0 - $69.71 $228,404 - $723,729
10,382 Added 16.82%
72,100 $4.83 Million
Q1 2024

May 15, 2024

BUY
$25.72 - $29.94 $828,646 - $964,606
32,218 Added 109.21%
61,718 $1.67 Million
Q4 2023

Feb 14, 2024

BUY
$23.42 - $31.74 $690,890 - $936,330
29,500 New
29,500 $914,000
Q2 2021

Aug 16, 2021

SELL
$24.17 - $36.01 $1.03 Million - $1.53 Million
-42,500 Closed
0 $0
Q1 2021

May 17, 2021

BUY
$32.28 - $44.3 $1.37 Million - $1.88 Million
42,500 New
42,500 $1.45 Million
Q1 2020

May 15, 2020

SELL
$13.63 - $33.98 $2.3 Million - $5.74 Million
-169,000 Closed
0 $0
Q4 2019

Feb 14, 2020

SELL
$16.12 - $24.98 $822,120 - $1.27 Million
-51,000 Reduced 23.18%
169,000 $4.04 Million
Q3 2019

Nov 14, 2019

SELL
$15.49 - $25.78 $3.34 Million - $5.56 Million
-215,500 Reduced 49.48%
220,000 $3.88 Million
Q2 2019

Aug 14, 2019

BUY
$23.0 - $32.19 $1.51 Million - $2.11 Million
65,500 Added 17.7%
435,500 $11.1 Million
Q1 2019

May 14, 2019

BUY
$13.91 - $31.15 $5.15 Million - $11.5 Million
370,000 New
370,000 $10.8 Million

Others Institutions Holding INSM

About INSMED Inc


  • Ticker INSM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 135,476,992
  • Market Cap $9.48B
  • Description
  • Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversibl...
More about INSM
Track This Portfolio

Track Acuta Capital Partners, LLC Portfolio

Follow Acuta Capital Partners, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Acuta Capital Partners, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Acuta Capital Partners, LLC with notifications on news.